AWM
IRD

Apollon Wealth Management’s Opus Genetics IRD Stock Holding History

Apollon Wealth Management’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-28,089
Closed -$27.6K – 1334
2025
Q1 		$27.6K Hold
28,089
– – ﹤0.01% 1191
2024
Q4 		$33.4K Buy
+28,089
New +$32.2K ﹤0.01% 1181

Other funds holding IRD

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
MBAM
Mink Brook Asset Management West Palm Beach, Florida $179M AUM 37.68% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Apollon Wealth Management's IRD Position: Q2 2025 in Review

Apollon Wealth Management sold out of Opus Genetics (IRD) in Q2 2025, closing a stake of 28,089 shares — an estimated $27.6K sold.

Apollon Wealth Management first reported a position in IRD in Q4 2024 and held it in 2 quarters. The position peaked at $33.4K in Q4 2024. 43 funds tracked by Wall St. Rank hold IRD as of Q2 2025.

  • Apollon Wealth Management reported no remaining Opus Genetics position as of Q2 2025 after selling out during the quarter.
  • Apollon Wealth Management sold 28,089 Opus Genetics shares in Q2 2025, an estimated $27.6K.
  • Apollon Wealth Management first reported a position in Opus Genetics in Q4 2024 and held it in 2 quarters.
  • Apollon Wealth Management's Opus Genetics position peaked at $33.4K in Q4 2024.
  • 43 funds tracked by Wall St. Rank held Opus Genetics as of Q2 2025.

Based on Apollon Wealth Management's 13F filing for Q2 2025, filed 25 Jul 2025.